These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 33744399

  • 1. Heart failure hospitalisation relative to major atherosclerotic events in type 2 diabetes with versus without chronic kidney disease: A meta-analysis of cardiovascular outcomes trials.
    Sacre JW, Magliano DJ, Shaw JE.
    Diabetes Metab; 2021 Sep; 47(5):101249. PubMed ID: 33744399
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.
    Filippatos G, Anker SD, Pitt B, Rossing P, Joseph A, Kolkhof P, Lambelet M, Lawatscheck R, Bakris GL, Ruilope LM, Agarwal R.
    JACC Heart Fail; 2022 Nov; 10(11):860-870. PubMed ID: 36328655
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial.
    Oulhaj A, Aziz F, Suliman A, Eller K, Bentoumi R, Buse JB, Al Mahmeed W, von Lewinski D, Coleman RL, Holman RR, Sourij H.
    Diabetes Obes Metab; 2024 Oct; 26(10):4602-4612. PubMed ID: 39086032
    [Abstract] [Full Text] [Related]

  • 8. Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.
    Htoo PT, Tesfaye H, Schneeweiss S, Wexler DJ, Everett BM, Glynn RJ, Kim SC, Najafzadeh M, Koeneman L, Farsani SF, Déruaz-Luyet A, Paik JM, Patorno E.
    JAMA Netw Open; 2022 Oct 03; 5(10):e2237606. PubMed ID: 36264574
    [Abstract] [Full Text] [Related]

  • 9. Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: A meta-analysis with trial sequential analysis.
    Qiu M, Ding L, Zhou H.
    Medicine (Baltimore); 2021 Mar 12; 100(10):e25121. PubMed ID: 33725910
    [Abstract] [Full Text] [Related]

  • 10. Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.
    Agarwal R, Pitt B, Rossing P, Anker SD, Filippatos G, Ruilope LM, Kovesdy CP, Tuttle K, Vaduganathan M, Wanner C, Bansilal S, Gebel M, Joseph A, Lawatscheck R, Bakris GL.
    JAMA Cardiol; 2023 Aug 01; 8(8):732-741. PubMed ID: 37314801
    [Abstract] [Full Text] [Related]

  • 11. Kidney Function as Risk Factor and Predictor of Cardiovascular Outcomes and Mortality Among Older Adults.
    Kühn A, van der Giet M, Kuhlmann MK, Martus P, Mielke N, Ebert N, Schaeffner ES.
    Am J Kidney Dis; 2021 Mar 01; 77(3):386-396.e1. PubMed ID: 33197533
    [Abstract] [Full Text] [Related]

  • 12. Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study.
    de Boer IH, Gao X, Cleary PA, Bebu I, Lachin JM, Molitch ME, Orchard T, Paterson AD, Perkins BA, Steffes MW, Zinman B, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group.
    Clin J Am Soc Nephrol; 2016 Nov 07; 11(11):1969-1977. PubMed ID: 27797889
    [Abstract] [Full Text] [Related]

  • 13. The kidney and cardiovascular outcome trials.
    Bloomgarden Z.
    J Diabetes; 2018 Feb 07; 10(2):88-89. PubMed ID: 29031006
    [Abstract] [Full Text] [Related]

  • 14. Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
    Sarraju A, Bakris G, Cannon CP, Cherney D, Damaraju CV, Figtree GA, Gogate J, Greene T, Heerspink HJL, Januzzi JL, Neal B, Jardine MJ, Blais J, Kosiborod M, Levin A, Lingvay I, Weir MR, Perkovic V, Mahaffey KW.
    J Am Coll Cardiol; 2022 Nov 01; 80(18):1721-1731. PubMed ID: 36302584
    [Abstract] [Full Text] [Related]

  • 15. Association Between Kidney Clearance of Secretory Solutes and Cardiovascular Events: The Chronic Renal Insufficiency Cohort (CRIC) Study.
    Chen Y, Zelnick LR, Huber MP, Wang K, Bansal N, Hoofnagle AN, Paranji RK, Heckbert SR, Weiss NS, Go AS, Hsu CY, Feldman HI, Waikar SS, Mehta RC, Srivastava A, Seliger SL, Lash JP, Porter AC, Raj DS, Kestenbaum BR, CRIC Study Investigators.
    Am J Kidney Dis; 2021 Aug 01; 78(2):226-235.e1. PubMed ID: 33421453
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Mann JFE, Fonseca V, Mosenzon O, Raz I, Goldman B, Idorn T, von Scholten BJ, Poulter NR.
    Circulation; 2018 Dec 18; 138(25):2908-2918. PubMed ID: 30566006
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.